MET and non-small cell lung carcinoma: To the best of our knowledge, our retrospective cohort study is the first to investigate the efficacy of EGFR-TKI alone or in combination with either crizotinib or chemotherapy in treatment-naïve NSCLC harboring concurrent EGFR sensitizing mutation and MET overexpression.